Receipt of requisite shareholder approvals allows the parties to proceed to completion
BF&M Limited (“BF&M”) (BSX: BFM) and Argus Group Holdings Limited (“Argus”) (BSX: AGH) announced today that, at their respective Special General Meetings held earlier today on 23 December 2024, their respective shareholders have voted overwhelmingly in favour of, in the case of Argus, the proposed amalgamation of Argus and Eleos Health Ltd., a wholly-owned subsidiary of BF&M, (the “Amalgamation”) and, in the case of BF&M, certain governance matters related thereto, previously announced on 28 June 2024.
Under the terms of the amalgamation agreement, receipt of approval from Argus shareholders of the Amalgamation, and receipt of approval from BF&M shareholders of certain governance matters related to the Amalgamation, were conditions to completion of the Amalgamation.
With these conditions now satisfied, the Amalgamation is expected to complete on 6 January 2025. Trading in BF&M’s shares and Argus’ shares will continue to be suspended pending closing of the Amalgamation.
Any content which is considered unsuitable, unlawful, or offensive, includes personal details, advertises or promotes products, services or websites, or repeats previous comments will be removed.
User comments posted on this website are solely the views and opinions of the comment writer and are not a representation of or reflection of the opinions of TNN or its staff.
TNN reserves the right to remove, edit or censor any comments.
TNN accepts no liability and will not be held accountable for the comments made by users.